Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study
T Nakano, K Kuribayashi, M Kondo… - Asia‐Pacific Journal …, 2021 - Wiley Online Library
Aims Malignant pleural mesothelioma (MPM) is an aggressive malignancy with poor
prognosis and limited treatment options. Cisplatin plus pemetrexed is the only approved first …
prognosis and limited treatment options. Cisplatin plus pemetrexed is the only approved first …
Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS …
G Zalcman, J Mazières, J Margery, L Greillier… - 2015 - ascopubs.org
7500 Background: MPM median overall survival (OS) did not exceed 13 months with
pemetrexed-platinum doublet, with virtually no surviving patients at 5 years. Vascular …
pemetrexed-platinum doublet, with virtually no surviving patients at 5 years. Vascular …
Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date
PA Levin, JE Dowell - OncoTargets and therapy, 2017 - Taylor & Francis
Malignant pleural mesothelioma (MPM) is a rare, but aggressive cancer. Surgery and
radiation offer limited benefit, and systemic chemotherapy remains the primary treatment …
radiation offer limited benefit, and systemic chemotherapy remains the primary treatment …
A review of bevacizumab in the treatment of malignant pleural mesothelioma
S Brosseau, S Assoun, C Naltet, C Steinmetz… - Future …, 2017 - Future Medicine
Malignant pleural mesothelioma (MPM) is an aggressive cancer with poor prognosis.
Systemic chemotherapy is the primary treatment modality for the majority of patients. VEGF …
Systemic chemotherapy is the primary treatment modality for the majority of patients. VEGF …
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
GL Ceresoli, PA Zucali, M Mencoboni, M Botta… - British journal of …, 2013 - nature.com
Background: The aim of this open label phase II study (NCT00407459) was to assess the
activity of the vascular endothelial growth factor (VEGF) inhibitor bevacizumab combined …
activity of the vascular endothelial growth factor (VEGF) inhibitor bevacizumab combined …
IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural …
G Zalcman, J Mazieres, A Scherpereel, J Margery… - 2012 - ascopubs.org
TPS7112 Background: MPM median OS does not exceed 13 months with pem/CDDP
doublet. US Intergroup phase II trial of gemcitabine/CDDP, with or without bevacizumab …
doublet. US Intergroup phase II trial of gemcitabine/CDDP, with or without bevacizumab …
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label …
G Zalcman, J Mazieres, J Margery, L Greillier… - The Lancet, 2016 - thelancet.com
Background Malignant pleural mesothelioma is an aggressive cancer with poor prognosis,
linked to occupational asbestos exposure. Vascular endothelial growth factor is a key …
linked to occupational asbestos exposure. Vascular endothelial growth factor is a key …
IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase II/III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural …
G Zalcman, J Margery, A Scherpereel… - Journal of Clinical …, 2010 - ascopubs.org
7020 Background: MPM median OS does not exceed 13 months with pem/CDDP doublet.
US Intergroup phase II trial of gemcitabine/CDDP, with or without bevacizumab, gave an …
US Intergroup phase II trial of gemcitabine/CDDP, with or without bevacizumab, gave an …
Pemetrexed maintenance therapy following bevacizumab-containing first-line chemotherapy in advanced malignant pleural mesothelioma: a case report and …
XQ Jing, L Zhou, XD Sun, JM Yu, X Meng - Medicine, 2016 - journals.lww.com
Malignant pleural mesothelioma (MPM) is a lethal disease with poor prognosis. The
combination of cisplatin and pemetrexed has been confirmed as the standard of care for …
combination of cisplatin and pemetrexed has been confirmed as the standard of care for …
Improvement of malignant pleural mesothelioma prognosis: early diagnosis and multimodality treatment
CJ Ban, HZ Shi, YH Zhang - Chinese Medical Journal, 2017 - mednexus.org
Chinese Medical Journal¦ January 5, 2017¦ Volume 130¦ Issue 1 2 was increased in the
bevacizumab plus chemotherapy when compared with chemotherapy alone. The NCCN …
bevacizumab plus chemotherapy when compared with chemotherapy alone. The NCCN …